BALLERUP, Denmark, December 11, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced that tralokinumab – an investigational, fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine –
Read our annual report
Featured stories
04-12-2019 LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device
21-11-2019 LEO Pharma launches Open Innovation in Ontario to support the innovation ecosystem in the province
14-11-2019 Birgitta Stymne Göransson elected member of LEO Pharma's Board of Directors
07-11-2019 LEO Science & Tech Hub and Epicore Biosystems Announce Second Phase of Partnership
30-10-2019 LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds
01-07-2019 LEO Pharma completes the acquisition of Bayer's prescription dermatology business
03-06-2019 LEO Pharma appoints Catherine Mazzacco as new CEO
11-04-2019 LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
The Global Leadership Team is responsible for overall business growth, strategic direction and daily operations.
Read more
We believe in making our activities and operations accessible to all relevant media
Read more
